Trinity Biotech reported a net loss of $24.0M for 2023, with revenues declining 9.1% to $56.8M. The decrease was mainly due to lower PCR Viral Transport Media sales, reduced laboratory services revenue, and lower haemoglobins revenues. The company recorded impairment charges of $11.1M primarily related to Immco Diagnostics.In January 2024, Trinity acquired Waveform Technologies' CGM assets for $12.5M in cash and 1.8M ADSs, plus contingent consideration up to $20M. The company also secured an amended credit agreement with Perceptive providing $22M additional funding, with $12.5M used for the Waveform acquisition and $9.5M for CGM development.The company announced a comprehensive transformation plan targeting operational efficiency through manufacturing consolidation, cost reductions, and business support function centralization. In April 2023, Trinity divested its Fitzgerald Industries business for approximately $30M, resulting in a $12.7M gain.

Trinity Biotech reported a net loss of $24.0M for 2023, with revenues declining 9.1% to $56.8M. The decrease was mainly due to lower PCR Viral Transport Media sales, reduced laboratory services revenue, and lower haemoglobins revenues. The company recorded impairment charges of $11.1M primarily related to Immco Diagnostics.In January 2024, Trinity acquired Waveform Technologies' CGM assets for $12.5M in cash and 1.8M ADSs, plus contingent consideration up to $20M. The company also secured an amended credit agreement with Perceptive providing $22M additional funding, with $12.5M used for the Waveform acquisition and $9.5M for CGM development.The company announced a comprehensive transformation plan targeting operational efficiency through manufacturing consolidation, cost reductions, and business support function centralization. In April 2023, Trinity divested its Fitzgerald Industries business for approximately $30M, resulting in a $12.7M gain.